A

Amgen

Makes biotech medicines for serious illnesses

Associate Director, Orchestration Engine

Full-TimeUpdated on 10/24/2026
$150.8k - $204k+ Annual bonus + Stock-based long-term incentives
Expert
Bachelor's, Master's, PhD, Associate's
Deerfield, IL, USA+1 moreMore locations: Thousand Oaks, CA, USA
HybridFlexible commuter role; onsite at least three days per week at either Thousand Oaks, California, or Deerfield, Illinois.
ProductProduct Management

About the job

Requirements
  • A doctorate degree and 3 years of experience in Commercial, Marketing, Sales, Medical, Analytics, Product Management, or a related function; or a master's degree and 5 years of such experience; or a bachelor's degree and 7 years of such experience; or an associate's degree and 12 years of such experience; or a high school diploma/GED and 14 years of such experience.
Responsibilities
  • Serve as the primary Orchestration Engine partner for assigned portfolio and brand teams.
  • Partner with brands to define desired cross-channel customer experiences and identify high-value orchestration opportunities.
  • Translate portfolio priorities into a sequenced backlog of Next Best Action, audience activation, journey orchestration, and workflow use cases.
  • Assess opportunities based on business value, customer and patient impact, readiness, feasibility, and potential for enterprise reuse.
  • Identify common requirements across brands and translate them into reusable decisioning patterns and activation capabilities.
  • Translate brand objectives and customer journey needs into business requirements, user stories, decision rules, and acceptance criteria.
  • Define how data, analytics, AI-generated recommendations, business rules, and human judgment should come together in operational workflows.
  • Co-design orchestration capabilities with Decision Sciences, Technology, CRM, CDP, content, channel, and vendor partners.
  • Define eligibility criteria, prioritization requirements, workflow handoffs, approval points, and business guardrails.
  • Ensure recommendations are relevant, explainable, compliant, and actionable within Marketing workflows.
  • Represent portfolio requirements while aligning to enterprise Orchestration Engine standards and architecture.
  • Provide business ownership from discovery and design through testing, deployment, and optimization.
  • Coordinate brand participation in workshops, requirements validation, user acceptance testing, and release readiness.
  • Partner with Technology and vendor teams to resolve requirements, dependencies, risks, and implementation decisions.
  • Coordinate rollout and adoption plans with brand, Marketing Operations, and change-management partners.
  • Drive adoption of Orchestration Engine capabilities across the assigned Marketing organization.
  • Gather user feedback and translate learnings into product, workflow, and roadmap enhancements.
  • Help extend successful capabilities efficiently across additional brands and use cases.
  • Apply enterprise standards for Next Best Action, decision logic, audience activation, journey orchestration, and human-led decision-making.
  • Ensure business rules, eligibility criteria, prioritization logic, and approval workflows are documented and governed.
  • Partner with Legal, Regulatory, Privacy, Compliance, and other control functions as appropriate.
  • Define success measures for assigned orchestration use cases.
  • Monitor adoption, recommendation utilization, workflow performance, and business impact with analytics partners.
  • Use performance data and stakeholder feedback to improve decisioning patterns and customer experiences.
  • Serve as the bridge between brand stakeholders, Decision Sciences, Technology, activation teams, and vendor partners.
  • Lead matrixed teams through requirements definition, design decisions, testing, deployment, and adoption.
  • Communicate portfolio roadmap progress, decisions, risks, dependencies, and impact.
  • Translate analytical, AI, and technical concepts into clear business implications and actionable recommendations.
  • Balance portfolio-specific needs with enterprise scalability and reuse.
Desired Qualifications
  • Experience partnering directly with pharmaceutical brand teams and commercial stakeholders.
  • Understanding of brand planning, omnichannel Marketing, customer engagement, and commercial workflows.
  • Experience acting as a business product owner or product lead, including requirements development, backlog management, testing, deployment, and adoption.
  • Experience translating customer journey needs into scalable workflows and business capabilities.
  • Familiarity with Next Best Action (NBA), customer relationship management (CRM), customer data platforms (CDP), audience targeting, marketing automation, content platforms, or channel activation.
  • Experience operationalizing analytics, machine-learning outputs, or AI-generated recommendations within business processes.
  • Ability to distinguish brand-specific needs from reusable enterprise capabilities.
  • Experience driving adoption of new platforms, tools, or workflows across Marketing teams.
  • Understanding of governance, privacy, compliance, and regulatory requirements in life sciences.
  • Demonstrated ability to lead matrixed teams spanning business, analytics, Technology, operations, and external vendors.
  • Ability to translate technical and analytical concepts into clear business requirements and recommendations.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.